AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering toRead More
Partnering to unlock the true potential of cannabis in medical care
Innoplexus and ChemAxon partner to get more out of life science data
Frankfurt, Germany – Budapest, Hungary, September 16, 2019 – Innoplexus announces an official partnership with ChemAxon, getting the most value out from life sciences data. Through the joint venture, Innoplexus will enable big pharma and biotech companies to find and connect information about pharmaceutical compounds from publicly available, or archived enterprise datasets to generate novel ideas.
ChemAxon provides best-in-class solutions in cheminformatics for the chemistry, biotechnology, pharmaceutical, and agrochemical industries. Innoplexus, a global leader in artificial intelligence (AI) and blockchain for the life sciences industry, will leverage one of ChemAxon’s products, ChemLocator, to search all potential, pre-clinical, clinical or marketed drugs in all documents across data assets in Innoplexus product, Ontosight® , to detect industry-relevant signals much earlier than traditional methods.
ChemLocator is a web-based search tool with chemical recognition capabilities that allows users to discover hidden chemical knowledge and extract structures from documents. Combining ChemLocator with Innoplexus computer vision and ontology will accelerate the time to find any chemical or compound using its name or chemical properties or even the structure from unstructured data available.
- ChemLocator offers a significant edge to Ontosight® users by allowing them to discover otherwise-unavailable information in public domains or “forgotten” information in enterprise archives such as competing or novel compounds in the area of interest.
- Connecting disparate information pieces across different public and enterprise documents, ChemLocator-backed Ontosight® accelerates the research by highlight non-obvious findings or discover unexplored whitespaces.
“The 4th Industrial Revolution is changing the world, and we are glad to be partnering with a leading AI company to tackle one of the most exciting challenges in the automated data process. We believe extracting chemical structures from scientific literature and facilitating meaningful questions related to those will leverage the transformation of existing information into novel ideas. We truly believe that our integration with Ontosight® will open up new perspectives for life sciences R&D.” David Jozsef, Product Owner of ChemLocator at ChemAxon.
Vatsal Agarwal, Vice President – Artificial Intelligence & Computational Linguistics at Innoplexus, expressed, “We look forward to integrate ChemLocator into Ontosight® to be able to deliver new possibilities to our clients together.” The decision to partner with ChemAxon was realized out of Innoplexus’ growing dedication to help its users find known as well as previously unknown insights related to biomedical entities and thus, improve how the pharma and biotech industry leverages life sciences data using automation.
The partnership between Innoplexus and ChemAxon will create opportunities to enrich life science research, allowing pharma and biotech companies to be innovative and faster in developing novel therapies.
About ChemAxon
ChemAxon is a chemical and biological software development company that provides solutions for the biotechnology and pharmaceutical industries; and widely used in publishing, flavors, fragrances, petroleum, and fine chemical research. The company offers out-of-the-box solutions for scientists, back- end tools for IT professionals, components to add extra functionality, and integrations to make our technology available from 3rd-party software like Microsoft Excel or KNIME.
Featured News
Strategic partnership announcement: Innoplexus holding company Partex NV is pleased
Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience.Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to announce…
AI supports targeted therapy recommendations fortumor diseases – BMBF funds
The treatment and support of patients with advanced tumor diseases is a complex task involving numerous disciplines. For the interdisciplinary…
Innoplexus and Innovatrix capital partner to bring about new risk-transfer
Artificial Intelligence (AI) pioneer Innoplexus and London based Parametric Insurance start-up, Innovatrix Capital, collaborating upon using AI & Machine Learning…
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence to expedite PIM kinase inhibitor development ESCHBORN, Germany, May 30,…
Parexel and Innoplexus Unveil Single Source of COVID-19 Information for
COVID-19 Clearinghouse enables direct access to latest COVID-19 datasets, publications, research and clinical trialsBOSTON and DURHAM, N.C. and ESCHBORN, Germany,…
New app for cancer patients
Das Eschborner Unternehmen Innoplexus hat eine neue App namens „Curia“ für Krebspatienten veröffentlicht. Mit dem Computerprogramm, das sich unentgeltlich herunterladen…
Innoplexus wins Silver Edison Award for OntosightⓇ Explore
Frankfurt, Germany, March 26, 2020 — Innoplexus AG has been honored with the Silver Edison Award 2020 for its proprietary…
AI CTP engine estimated failure for Biogen’s aducanumab
While drug development can be incredibly lucrative, it is a very risky business. German company Innoplexus has developed a domain-specific…
How can AI be leveraged for Clinical Trial Prediction?
Successful clinical trials occur at a ratio of 1 in 10, costing around $2-$3 billion, with drugs taking 10–12 years…
Innoplexus launches new Blockchain platform for Pharma innovation
If your loved one was diagnosed with a potentially fatal illness, wouldn’t you want all the information possible to be…